PMID- 33330547
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201218
IS  - 2296-858X (Print)
IS  - 2296-858X (Electronic)
IS  - 2296-858X (Linking)
VI  - 7
DP  - 2020
TI  - Classical Disease-Specific Autoantibodies in Systemic Sclerosis: Clinical 
      Features, Gene Susceptibility, and Disease Stratification.
PG  - 587773
LID - 10.3389/fmed.2020.587773 [doi]
LID - 587773
AB  - Systemic sclerosis (SSc) is an autoimmune disease characterized by abnormalities 
      in microcirculation, extracellular matrix accumulation, and immune activation. 
      Autoantibodies are markers of immune abnormalities and provide diagnostic and 
      predictive value in SSc. Anti-topoisomerase antibodies (ATAs), anticentromere 
      antibodies (ACAs), and anti-RNA polymerase antibodies (ARAs) are the three 
      classical specific antibodies with the highest availability and stability. In 
      this review, we provide an overview of the recent progress in SSc research with 
      respect to ATAs, ACAs, and ARAs, focusing on their application in distinguishing 
      clinical phenotypes, such as malignancy and organ involvement, identifying 
      genetic background in human leukocyte antigen (HLA) or non-HLA alleles, and their 
      potential roles in disease pathogenesis based on the effects of antigen-antibody 
      binding. We finally summarized the novel analysis using ATAs, ACAs, and ARAs on 
      more detailed disease clusters. Considering these advantages, this review 
      emphasizes that classical SSc-specific autoantibodies are still practical and 
      have the potential for patient and risk stratification with applications in 
      precise medicine for SSc.
CI  - Copyright (c) 2020 Yang, Tang, Zhu, Ding and Qiao.
FAU - Yang, Changyi
AU  - Yang C
AD  - Department of Dermatology, The First Affiliated Hospital, Zhejiang University 
      School of Medicine, Hangzhou, China.
FAU - Tang, Shunli
AU  - Tang S
AD  - Department of Dermatology, The First Affiliated Hospital, Zhejiang University 
      School of Medicine, Hangzhou, China.
FAU - Zhu, Dingxian
AU  - Zhu D
AD  - Department of Dermatology, The First Affiliated Hospital, Zhejiang University 
      School of Medicine, Hangzhou, China.
FAU - Ding, Yingguo
AU  - Ding Y
AD  - Department of Dermatology, The First Affiliated Hospital, Zhejiang University 
      School of Medicine, Hangzhou, China.
FAU - Qiao, Jianjun
AU  - Qiao J
AD  - Department of Dermatology, The First Affiliated Hospital, Zhejiang University 
      School of Medicine, Hangzhou, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201119
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC7710911
OTO - NOTNLM
OT  - anti-RNA polymerase antibodies
OT  - anti-topoisomerase antibodies
OT  - anticentromere antibodies
OT  - clinical manifestations
OT  - disease stratification
OT  - gene
OT  - systemic sclerosis
EDAT- 2020/12/18 06:00
MHDA- 2020/12/18 06:01
PMCR- 2020/11/19
CRDT- 2020/12/17 05:54
PHST- 2020/07/27 00:00 [received]
PHST- 2020/10/08 00:00 [accepted]
PHST- 2020/12/17 05:54 [entrez]
PHST- 2020/12/18 06:00 [pubmed]
PHST- 2020/12/18 06:01 [medline]
PHST- 2020/11/19 00:00 [pmc-release]
AID - 10.3389/fmed.2020.587773 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2020 Nov 19;7:587773. doi: 10.3389/fmed.2020.587773. 
      eCollection 2020.